Skip to main content

Table 3 KRAS agreement study between GeneReader and Pyrosequencing and Therascreen PCR Assays

From: Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform

>5% KRAS variant allele frequency cut off Pyrosequencing and Therascreen PCR Assays(a)
(MT) (WT) Total
GeneReader NGS System(b) (MT) 14 0 14
(WT) 0 29 29
Total 14 29 43
  1. (a)If KRAS is mutant by Therascreen KRAS RGQ PCR assay or Therascreen RAS extension Pyrosequencing assay, the condition is recorded as a mutant (MT)
  2. (b)For Actionable Insights Tumor Panel, a 5% allelic frequency cut off was used to call variants for codon 12, 13, 59, 61, 117 and 146, which are addressed by established QIAGENTherascreen PCR assays